# Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

> **NCT00707655** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genmab** · enrollment: 8 (actual)

## Conditions studied

- Head and Neck Cancer
- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Zalutumumab

## Key facts

- **NCT ID:** NCT00707655
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The decision is based on company re-evaluation of indications to be pursued within SCCHN
- **Last updated:** 2023-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00707655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00707655, "Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00707655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*